Phase I/II study of the Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor BSI-201 in patients with newly diagnosed malignant glioma

Trial Profile

Phase I/II study of the Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor BSI-201 in patients with newly diagnosed malignant glioma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Iniparib (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2015 Planned End Date changed from 1 Apr 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top